Lundbeck enters into license agreement with Kyowa Hakko Kirin for A2a antagonists for Parkinson's and other indications

07-Oct-2010 - Denmark

H. Lundbeck A/S announced that it has signed an agreement with Kyowa Hakko Kirin Co., Ltd. providing Lundbeck with exclusive rights to develop and commercialise the adenosine A2a antagonist KW-6356. Lundbeck will also have the right to further select compounds as either back-up or additional indication compounds. Adenosine A2a antagonists have potential applications in a wide range of therapeutic indications, including Parkinson's disease. Kyowa Hakko Kirin will retain rights to develop and commercialise the compounds in Japan and the Asian region.

Kyowa Hakko Kirin will receive an upfront payment, development and commercial milestones, as well as royalties on net sales from Lundbeck.

KW-6356 is in early development and is a selective, high-affinity and long-lasting antagonist of the adenosine A2a receptor conferring strong efficacy in various disease models.

The agreement is an important supplement to Lundbeck's commitment to provide new innovative medicines in the CNS field in areas with high unmet need.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances